logo-loader

Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian cancer

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer.

The CEO said the first part of the study has shown some very promising signals, and the data from Part B will significantly enhance understanding of the drug.

The company will be presenting data to the upcoming ESMO conference in September.

Kazia is also making news with its treatment strategies for different types of brain cancer.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Emmerson Resources discusses recent diamond drilling...

Emmerson Resources Ltd (ASX:ERM) managing director and CEO Rob Bills updates Proactive on the first diamond drilling activities at the Whatling Hill Project in NSW.  A 1,500-metre reverse circulation (RC) and diamond drilling program is targeting an interpreted porphyry copper-gold...

20 hours, 49 minutes ago

2 min read